These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22138540)

  • 1. Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings--implications for intervention impact.
    Vickerman P; Martin NK; Hickman M
    Drug Alcohol Depend; 2012 Jun; 123(1-3):122-31. PubMed ID: 22138540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?
    Vickerman P; Martin NK; Roy A; Beattie T; Jarlais DD; Strathdee S; Wiessing L; Hickman M;
    Drug Alcohol Depend; 2013 Sep; 132(1-2):172-81. PubMed ID: 23453261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users.
    de Vos AS; van der Helm JJ; Prins M; Kretzschmar ME
    Epidemics; 2012 Jun; 4(2):57-67. PubMed ID: 22664064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users.
    Murray JM; Law MG; Gao Z; Kaldor JM
    Int J Epidemiol; 2003 Oct; 32(5):708-14. PubMed ID: 14559736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of HIV, hepatitis B and hepatitis C and associated risk behaviours amongst injecting drug users in three Afghan cities.
    Nasir A; Todd CS; Stanekzai MR; Bautista CT; Botros BA; Scott PT; Strathdee SA; Tjaden J
    Int J Drug Policy; 2011 Mar; 22(2):145-52. PubMed ID: 21146392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a needle social marketing strategy to control HIV among injecting drug users in China.
    Wu Z; Luo W; Sullivan SG; Rou K; Lin P; Liu W; Ming Z
    AIDS; 2007 Dec; 21 Suppl 8():S115-22. PubMed ID: 18172379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
    Vicknasingam B; Narayanan S; Navaratnam V
    Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam.
    Van Ameijden EJ; Van den Hoek JA; Mientjes GH; Coutinho RA
    Eur J Epidemiol; 1993 May; 9(3):255-62. PubMed ID: 8405310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001.
    Des Jarlais DC; Perlis T; Arasteh K; Torian LV; Hagan H; Beatrice S; Smith L; Wethers J; Milliken J; Mildvan D; Yancovitz S; Friedman SR
    AIDS; 2005 Oct; 19 Suppl 3():S20-5. PubMed ID: 16251819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV and hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway.
    Miller M; Mella I; Moi H; Eskild A
    J Acquir Immune Defic Syndr; 2003 Jul; 33(3):373-9. PubMed ID: 12843749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.
    Stark K; Müller R; Bienzle U; Guggenmoos-Holzmann I
    AIDS; 1996 Mar; 10(3):311-7. PubMed ID: 8882671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidence.
    Fraser H; Mukandavire C; Martin NK; Hickman M; Cohen MS; Miller WC; Vickerman P
    Int J Epidemiol; 2017 Apr; 46(2):466-478. PubMed ID: 27524816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High regional variability of HIV, HCV and injecting risks among people who inject drugs in Poland: comparing a cross-sectional bio-behavioural study with case-based surveillance.
    Rosińska M; Sierosławski J; Wiessing L
    BMC Infect Dis; 2015 Feb; 15():83. PubMed ID: 25879904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin.
    Stark K; Bienzle U; Vonk R; Guggenmoos-Holzmann I
    Int J Epidemiol; 1997 Dec; 26(6):1359-66. PubMed ID: 9447418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004.
    Falster K; Kaldor JM; Maher L;
    J Urban Health; 2009 Jan; 86(1):106-18. PubMed ID: 18979201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.
    Todd CS; Nasir A; Stanekzai MR; Fiekert K; Sipsma HL; Vlahov D; Strathdee SA
    Harm Reduct J; 2015 Oct; 12():22. PubMed ID: 26472126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004.
    Burt RD; Hagan H; Garfein RS; Sabin K; Weinbaum C; Thiede H
    J Urban Health; 2007 May; 84(3):436-54. PubMed ID: 17356901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
    Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
    Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan.
    Vickerman P; Platt L; Hawkes S
    Sex Transm Infect; 2009 Apr; 85 Suppl 2():ii23-30. PubMed ID: 19307347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle/syringe exchange.
    Goldberg D; Burns S; Taylor A; Cameron S; Hargreaves D; Hutchinson S
    Scand J Infect Dis; 2001; 33(6):457-61. PubMed ID: 11450866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.